Solid investor interest as Ambit raises new funds for quizartinib-led pipeline
This article was originally published in Scrip
Ambit Biosciences closed the first $25 million tranche of a $50 million preferred stock financing to support late-stage development of its lead drug candidate quizartinib (AC220), as the private San Diego-based company prepares its Phase II data in the treatment of acute myeloid leukemia (AML) for presentation at the American Society of Hematology (ASH) annual meeting.
You may also be interested in...
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.